lung cancer
Conditions
Interventions
Case group:None
Sponsors
Taizhou hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Sign the informed consent form; 2. Male or female patients, age = 18 years old, when signing the informed consent form; 3. The researcher judged that he could comply with the research protocol; 4. Expected survival time = 10 months; 5. Histological or cytological examination confirms that patients with locally advanced (stage IIIB or stage IIIC) or metastatic (stage IV) non-squamous NSCLC that cannot undergo radical surgery or radiotherapy (according to the staging system of the International Anti-Cancer Union/American Cancer Federation, revised version 8), note: for patients with mixed histologic (i.e. squamous and non-squamous) tumors, if the main histological components appear to be non-squamous, they meet the requirements; 6. Have not received any anti-tumor treatment in the past; 7. According to the RECIST v1.1 standard, the expression of PD-L1 in measurable lesions is = 1%, and the samples are from previously obtained archived tumor tissues or tissues obtained from biopsy during screening; 8.ECOG PS: 0-1
Exclusion criteria
Exclusion criteria: 1. NSCLC diagnosed with EGFR sensitive mutation, ALK or ROS1 gene rearrangement; 2. During screening and before radiological imaging evaluation, active brain metastasis or leptomeningeal metastasis was confirmed by CT or MRI evaluation; 3. Untreated chronic hepatitis B patients or chronic hepatitis B virus carriers and active hepatitis C patients with HBV DNA = 500 IU/mL.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS rate at 6 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactXu Youzu
Taizhou hospital
Outcome results
None listed